Idogen recruits a new Chief Medical Officer
Idogen AB (“Idogen”) announces that Christina Brattström has been appointed Chief Medical Officer. She has solid experience in clinical development of transplantation drugs, and over 20 years of experience in senior medical roles at international pharmaceutical companies. Christina Brattström will be part of the company’s executive management and will take up her post on 1 April 2020.
Christina Brattström is a physician and completed her graduate studies at Karolinska Institutet, where she worked as Associate Professor and was responsible for clinical drug trials in transplantation medicine. Since 2000, she has held several senior positions in the pharmaceutical industry and will bring a broad range of experience from both the clinical development and regulatory spheres. Previously, Christina Brattström worked at Wyeth in roles including Senior Medical Advisor and head of CRA Group with responsibility for clinical trials. In addition, Christina worked for Abbot as Medical Director and head of one of the company’s regulatory affairs groups. She comes most recently from the pharmaceutical company Bayer AB, where she was Medical Director Scandinavia with medical responsibilities that included haemophilia drugs.
“We are pleased and proud that Christina Brattström has accepted the role of Chief Medical Officer at Idogen. Her broad range of experience in the field of transplantation, clinical trials and biological pharmaceuticals will be an important addition to our company,” says Anders Karlsson, CEO of Idogen.
Christina Brattström will take up a role in the development group that is preparing Idogen’s tolerogenic cell therapy for clinical trials. The first trial of the company’s most advanced project, IDO-8, is expected to begin in early 2021. IDO-8 will be evaluated in patients with severe haemophilia A who have developed antibodies against factor VIII therapy.
“Idogen’s technology has the potential to revolutionise the treatment of a range of diseases in which the body’s immune defence has stopped acting in the patient’s best interests, and I am looking forward to contributing my knowledge of applied transplantation immunology and clinical development,” says Christina Brattström, the incoming CMO at Idogen.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Tel: +46 70 918 00 10
The information was submitted for publication, through the agency of the contact persons set out above, on March 23, 2020.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of haemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.